ONCODES.PREC.MED. EO-34 (ZR8) — Net Asset Quality Index
ONCODES.PREC.MED. EO-34 (ZR8) has a Net Asset Quality Index of -4.0% as of December 2024. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €10.71 Million minus total liabilities of €11.14 Million yields net assets of €-429.39K. A higher index indicates a stronger, lower-leverage balance sheet. See ZR8 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
ONCODES.PREC.MED. EO-34 Net Asset Quality Index Over Time (2021–2024)
This chart shows how ONCODES.PREC.MED. EO-34's Net Asset Quality Index has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the index stands at -4.0%, representing net assets of €-429.39K against total assets of €10.71 Million EUR. Also explore ONCODES.PREC.MED. EO-34 assets under control for the complete picture of this company's asset base.
Annual Net Asset Quality Index for ONCODES.PREC.MED. EO-34 (2021–2024)
The table below presents the year-by-year Net Asset Quality Index for ONCODES.PREC.MED. EO-34 from 2021 to 2024, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see ONCODES.PREC.MED. EO-34 market cap and net worth.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | -4.0% | €-429.39K | €10.71 Million | €11.14 Million | ▼ -26.2 pp |
| 2023 | 22.2% | €3.69 Million | €16.63 Million | €12.94 Million | ▼ -41.9 pp |
| 2022 | 64.1% | €11.78 Million | €18.37 Million | €6.59 Million | ▲ +14.0 pp |
| 2021 | 50.2% | €4.20 Million | €8.37 Million | €4.17 Million | — |